Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Optimal Esketamine Dose for Prevention of Postpartum Depression
ChiCTR2600128246Phase 4Not yet recruiting
- Sponsor
- First Affiliated Hospital of Chongqing Medical University
- Start
- Jul 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of esketamine in postpartum depression (PPD), sponsored by First Affiliated Hospital of Chongqing Medical University. Primary endpoints: Occurrence of adverse events and Incidence of postpartum depression. Planned start Jul 2026; status: not yet recruiting.
02
Drugs
esketamine
03
Conditions
postpartum depression (PPD)
Beyond the preview
Go deeper on ChiCTR2600128246.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600128246.